Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. (NASDAQ: SANA) is a biotechnology company focused on creating and delivering engineered cells as medicines, and its news flow reflects this emphasis on cell and gene-based therapies. Company press releases and updates describe progress across its hypoimmune platform for allogeneic cell therapies and its fusogen platform for in vivo delivery of genetic payloads.
Investors following SANA news can read about clinical and preclinical milestones in type 1 diabetes, B-cell cancers, and B-cell–mediated autoimmune diseases. Sana has reported investigator-sponsored clinical data for UP421, a primary human pancreatic islet cell therapy engineered with hypoimmune technology, including results showing survival and function of transplanted beta cells without immunosuppression. News items also cover development of SC451, an O-negative, HIP-modified, iPSC-derived pancreatic islet cell therapy, and in vivo CAR T candidates such as SG299 and SG293 built on the fusogen platform.
In addition to scientific and clinical updates, Sana’s news includes quarterly financial results, portfolio prioritization decisions, and capital-raising activities through public offerings and at-the-market equity programs. The company also issues announcements about participation in healthcare and investor conferences, where management provides business overviews and program updates.
This news page aggregates these disclosures so readers can monitor developments in Sana’s engineered cell programs, regulatory interactions, scientific publications, and financing events associated with the SANA stock. For investors and observers of the biotechnology sector, the SANA news stream offers insight into how the company is advancing its platforms and concentrating resources on type 1 diabetes and in vivo CAR T approaches.
Sana Biotechnology (Nasdaq: SANA), a company specializing in engineered cells, has announced a proposed public offering of $75.0 million in common stock and pre-funded warrants. The company will also grant underwriters a 30-day option to purchase up to an additional $11.25 million of common stock.
The offering will be managed by joint book-running managers Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen. The offering will be made through a Registration Statement on Form S-3 previously filed with the SEC.
Sana Biotechnology (NASDAQ: SANA) has achieved a groundbreaking milestone in treating Type 1 diabetes, as published in the New England Journal of Medicine. The company successfully transplanted hypoimmune (HIP)-modified pancreatic islet cells in a 42-year-old patient with type 1 diabetes, marking the first successful transplantation without immunosuppression.
The study demonstrated that the transplanted cells survived, evaded immune detection, and produced insulin over a 12-week period, with additional positive data at 6 months. The patient, who had lived with diabetes for over three decades, showed measurable insulin production for the first time in 35 years.
Building on these results, Sana is developing SC451, a HIP-modified, stem cell-derived therapy, with plans to file an IND application as early as 2026. The company aims to provide a one-time treatment for type 1 diabetes patients that enables normal blood glucose levels without requiring insulin or immunosuppression.
Flagship Pioneering has unveiled Terrana Biosciences, a new agricultural technology company developing RNA-based solutions for crop enhancement and protection. The company emerges with an initial $50 million commitment from Flagship Pioneering after four years of platform development.
Terrana's proprietary RNA technology platform enables the development of targeted products that can work throughout a plant's lifecycle, creating solutions that adapt to variable climate conditions. The company has already demonstrated proof of concept in tomatoes, corn, and soy, and generated a pipeline of over 15 potential products in specialty and row crops.
The company's platform leverages AI and computational models to assemble a vast RNA library and design system for creating novel functional crop traits. Their solutions aim to help farmers combat diseases and pests, adapt to climate conditions, and maintain soil health, while offering advantages over conventional approaches in terms of timing flexibility and environmental impact.
Sana Biotechnology (NASDAQ: SANA), a company specializing in engineered cell therapies, has announced its participation in the BofA Securities 2025 Healthcare Conference. The company's President and CEO, Steve Harr, will deliver a business overview and update during a presentation scheduled for May 13, 2025, at 9:20 a.m. PT. The presentation will be accessible via webcast on Sana's Investor Relations website, with a replay available for 30 days after the event.
Cellarity has appointed Ted Myles as its new Chief Executive Officer and CEO-Partner at Flagship Pioneering. Myles brings extensive biopharma leadership experience, previously serving as CFO and COO of Scholar Rock where he raised over $1 billion and led the company through a successful Phase 3 study. His prior roles include executive positions at AMAG Pharmaceuticals, Ocata Therapeutics, and PrimeraDx.
The appointment comes as Cellarity prepares for its first clinical study in 2025. The company leverages an AI/ML-enabled platform for drug discovery, focusing on understanding dysregulated pathways in diseased human cells. Their lead program, CLY-124, is a potential first-in-class small molecule for sickle cell disease treatment, targeting fetal hemoglobin induction through a novel mechanism, with clinical development expected to begin in mid-2025.
Flagship Pioneering and Quotient Therapeutics have appointed Rahul Kakkar, M.D. as CEO-Partner and Chief Executive Officer. Dr. Kakkar brings nearly 20 years of experience in biotech entrepreneurship and medicine, previously serving as CEO of Tome Biosciences and Pandion Therapeutics, which was acquired by Merck for $1.85 billion.
Jake Rubens, Quotient's co-founder and former CEO, will transition to a board director role after successfully establishing the company's first industrial platform for discovering drug targets through somatic genomics and securing a collaboration with Pfizer in cardiovascular and renal diseases.
Dr. Kakkar, who continues to practice at Brigham and Women's Hospital and lecture at Harvard Medical School, will lead Quotient's efforts in advancing its pipeline and platform technology. The company's focus on somatic genomics aims to discover novel drug targets and create first-in-class medicines for various diseases.